Another win this week for psilocybin mushrooms in Hawaii. And the DEA is facing challenges to its newest proposal to ban five tryptamines.
Big news out of the UK! M.A.P.S. landed an Innovation Passport for MDMA as an adjunct to therapy for PTSD.
Why did the Director of the National Institute on Drug Abuse say the “train has left the station” on psychedelics?
This week: a new study suggests ketamine may be an effective treatment to sustain abstinence from alcohol
Was the original Santa Clause an Arctic shaman? And a new setback for trials of LSD for the treatment of generalized anxiety disorder (GAD)
A New York lawmaker introduced a bill to legalize psilocybin for medical purposes, and three Canadians get permission to use psilocybin.
Research suggests microdosing reduces anxiety and depression, and the first formal test of the effect of psychedlics on metaphysical beliefs.
This week: psychedelic stocks took a nosedive on Tuesday, and Novamind secures insurance coverage for ketamine from four major providers.
Welcome to This Week in Psychedelics! Find out which US city just approved a ballot initiative to decriminalize psychedelics.
Activists press Oakland, CA to allow local producers to sell ethnogenic substances, UK Prime Minister Boris Johnson to consider reclassifying psilocybin
Pennsylvania, Denver and Detroit consider psilocybin decriminalization and/or therapy
New research indicates psychedelics can reduce opioid use by 55%. And microdosing is in the spotlight of a new study by MindMed.
Genentech's multiple sclerosis treatment shows major promise; atai Beckley to meet with the FDA about its new depression treatment.
.png){kind=small}
